💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Valeant gives Pershing Square a seat on its board

Published 03/09/2016, 08:12 AM
Updated 03/09/2016, 08:20 AM
© Reuters.  Valeant gives Pershing Square a seat on its board
BHC
-
SQ
-

(Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) (TO:VRX), under scrutiny for its accounting and business practices, said it had given shareholder Pershing Square (NYSE:SQ) Capital Management a seat on its board and added two additional directors.

Stephen Fraidin, a veteran Wall Street lawyer who is vice chairman at William Ackman's Pershing Square, has joined the board, along with Fred Eshelman and Thomas Ross, Valeant said.

Anders Lonner has stepped down as a director, the company said on Wednesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.